Hemato-oncologist, Tata Memorial Center
Mumbai
Joined December 2014
- Tweets1.6K
- Following1.3K
- Followers3.1K
- Likes7.3K
Pinned Tweet
Happy to see our maintenance study in primary CNS lymphoma active & recruiting. Small but trying to see if this (feasible) Rx ? useful. Developed @ #acord2018 Thanks @MartinStockler @HariMenon68 . @oncologician @IJMPOofficial @VanitaNoronha @DrPMPGI ctri.nic.in/Clinicaltrials/p…
Bhausaheb Bagal retweeted
We will be presenting data on venetoclax in IgM AL, a difficult to treat entity with limited effective options.
#iwwm13
Bhausaheb Bagal retweeted
Christopher P. Fox, University of Nottingham, UK, discusses the efficacy of Glofit-GemOx across clinically relevant subgroups of patients with DLBCL based on 3-year follow-up data of the STARGLO trial.
Watch the full video here: bit.ly/4dStc7K
#Lymphoma #lymsm #MedEd #MedNews @ProfChrisPFox
Bhausaheb Bagal retweeted
In this blog, Sue Massey discusses parenting while living with multiple myeloma — talking with her children about cancer, finding support, and drawing strength from faith. myeloma.org/blog/one-moms-st…
Congratulations @VedangMurthy !!!
Some moments in any academic life are defining... One near the top is being invited to deliver the visiting prof grand rounds to the bright and curious minds of the @HarvardRadOnc residents!
Showered with love and warmth Hope you enjoyed as much as I did. 🙏🏼 @DrPaulNguyen
Bhausaheb Bagal retweeted
🩺 Smart monitoring can help nurses recognize important changes in a patient’s condition early.
Join HCC’s 58th Nursing Webinar:
Smart Patient Monitoring in Hematology-Oncology
🎙️ Mr. Sajad Hussain Naik
📅 29 Sept | ⏰ 3–4 PM IST
🔗 Join on Zoom
#OncologyNursing #Hematology
Dr Aditya, ready to present our SABIMA study at #IMS26, join in person or virtually !
Bhausaheb Bagal retweeted
1/🚀 #IMS2026: Can a CELMoD deepen and sustain responses to a BCMA bispecific in RRMM?
Dr. Ja Min Byun presented updated Part 1 results from MELT-MM, evaluating mezigdomide + elranatamab. The early efficacy signal is striking—but needs context. 🧵 #mmsm
MELT-MM enrolled patients with RRMM after ≥2 prior lines. The efficacy-evaluable cohort included 13 patients treated with:
• Mezigdomide 0.3 mg: n=7
• Mezigdomide 0.6 mg: n=6
Median follow-up: 13.7 months.
#mmsm #myeloma #MedEd #medtwitter #USMIRC @US_HMC @USMIRCNEWS @Larvol @oncodaily #IMS26 @OpenMedKate
Bhausaheb Bagal retweeted
450th Whipples at our centre
@TMC_Varanasi @EAHPBA @IHPBA @cw_michalski @Shrikhande_SV @SanjayGovil8
Bhausaheb Bagal retweeted
#IMS26 #mmsm Oral- % of functional cure with the use of Tec-Dara @Myeloma_Society
Estimated functional cure of 87% with Tec-Dara showing excellent promise of such therapy.
➡️Future will need time limited therapy (Stop and see what will happen)
➡️Assess cumulative toxicity with longer use of this therapy (infections most imp)- Non relapse mortality will be imp
Future is bright in myeloma
Bhausaheb Bagal retweeted
#IMS26 Plenary presentation for CERVINO demonstrates clear superiority of TCEs over SOC!
👏👏@PlasmaCellPete @myelomaMD et al.
12-mo PFS of 62.1% with Etentamig vs. 28.4% with control (Kd, SVd, EloPd)
OS showing encouraging trend as well!
Surely no more non TCE control arms in this setting going forward!
What’s different with Etentamig vs. other BCMA bispecifics:
Etentamig with its silenced fc tail offers longer administration intervals and lower CRS rates from lower CD3-binding affinity
Prophylactic toci is the way to go! Key for community uptake
You are with the boss, I am sure you will have fun learning !!!
An amazing week at ACORD 2026 Protocol Dev Workshop in Sydney. The faculties were truly inspiring and motivating us to go out and conquer the world! Thank you @MartinStockler @BelindaKiely @oncodocsydney @JiaJennyLiu @herbloong @nickymitchell @ChrisKarapetis #ACORD
Bhausaheb Bagal retweeted
Are we rewriting the toxicity signal with BCMA bispecific antibodies in myeloma? Perhaps…#IMS26
Bhausaheb Bagal retweeted
First RCT results of Etentamig (BCMA bispecifc antibody) presented at Plenary Session #IMS26 @Myeloma_Society @PlasmaCellPete
@myelomaMD
60 mg fixed dose every 4 weeks makes this the easiest bispecific to administer.
Impressive PFS benefit in relapsed refractory myeloma with at least 2 prior lines of therapy. See thread for more details.
Bhausaheb Bagal retweeted
Excited to be presenting here at #IMS26 tomorrow in the session entitled "Future Targets and New Modalities of Therapy". @SagarLonialMD and Kwee Yong are chairs. Hall 5, 9:30-10:20am. I'll share the 5-step formula @JNJInnovMed has been following towards #cure.
Bhausaheb Bagal retweeted
Dr Holly Lee @hollyleeYJ presenting at #IMS23 updated data and novel mechanisms on TNFRSF17 mutations and resistance to anti-BCMA redirecting therapies
Lively discussions and spirited debate and important patients perspectives on current in myeloma, great session ! @AhlstromJenny @MyelomaOslo @GKaurMD @RahulBanerjeeMD
Bhausaheb Bagal retweeted
Late-Breaking Abstract at #IMS2026.
Proud to share our Fortis real-world talquetamab (Which is still not available commercially in the country) data on the global myeloma stage.
Grateful to @RahulDoc2 for the encouragement to turn clinical experience into meaningful data.
#MMsm #IMS2026
Bhausaheb Bagal retweeted
MIDAS (Isa-Iberdomide maintenance)
🧬 #IMS26: MIDAS: Isatuximab + iberdomide maintenance drives MRD conversion in MRD-positive TE-NDMM pts post Isa-KRd:
💡MRD-neg (10⁻⁶) rates rising 40%→58%.
💡Encouraging depth, but only 1-yr data so far
💡will conversions translate into meaningful PFS/OS benefit long-term? #MultipleMyeloma #MMsm #MRD @Myeloma_Society
